271 related articles for article (PubMed ID: 11776490)
1. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR
Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490
[TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
Liénard D; Eggermont AM; Koops HS; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune FJ
Melanoma Res; 1999 Oct; 9(5):491-502. PubMed ID: 10596916
[TBL] [Abstract][Full Text] [Related]
3. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
4. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma.
Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K
Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases.
Deroose JP; Grünhagen DJ; van Geel AN; de Wilt JH; Eggermont AM; Verhoef C
Br J Surg; 2011 Nov; 98(11):1573-80. PubMed ID: 21739427
[TBL] [Abstract][Full Text] [Related]
6. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
Deroose JP; Grünhagen DJ; Eggermont AM; Verhoef C
Melanoma Res; 2015 Oct; 25(5):427-31. PubMed ID: 26110555
[TBL] [Abstract][Full Text] [Related]
7. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
Hoekstra HJ; Veerman K; van Ginkel RJ
J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
[TBL] [Abstract][Full Text] [Related]
9. Isolated limb perfusion in primary and recurrent melanoma: indications and results.
Liénard D; Eggermont AM; Kroon BB; Schraffordt Koops H; Lejeune FJ
Semin Surg Oncol; 1998; 14(3):202-9. PubMed ID: 9548602
[TBL] [Abstract][Full Text] [Related]
10. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
12. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma.
Vrouenraets BC; Hart GA; Eggermont AM; Klaase JM; van Geel BN; Nieweg OE; Kroon BB
J Am Coll Surg; 1999 May; 188(5):522-30. PubMed ID: 10235581
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for survival after isolated limb perfusion for malignant melanoma.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2003 Dec; 29(10):916-21. PubMed ID: 14624788
[TBL] [Abstract][Full Text] [Related]
14. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
15. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.
Grünhagen DJ; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg; 2004 Dec; 240(6):939-47; discussion 947-8. PubMed ID: 15570199
[TBL] [Abstract][Full Text] [Related]
16. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology.
Sanki A; Kam PC; Thompson JF
Ann Surg; 2007 Apr; 245(4):591-6. PubMed ID: 17414608
[TBL] [Abstract][Full Text] [Related]
18. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma.
Olofsson R; Mattsson J; Lindnér P
Int J Hyperthermia; 2013 Sep; 29(6):551-7. PubMed ID: 23865737
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A
In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]